Actively Recruiting
Phase III Randomized Trial Comparing Re-Radiochemotherapy Plus Pembrolizumab Versus Pembrolizumab with or without Chemotherapy in PD-L1 Positive Recurrent Head and Neck Cancer
Led by Universität des Saarlandes · Updated on 2026-09-10
214
Participants Needed
24
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether combining re-radiochemotherapy Re-RCT followed by pembrolizumab immunotherapy improves overall survival compared to pembrolizumab alone, with or without chemotherapy, in adults with locoregionally recurrent PD-L1 positive head and neck squamous cell carcinoma HNSCC. This phase III randomized controlled trial focuses on patients whose tumors have a combined positive score CPS of at least 1 and who have previously received radiation therapy to the neck at least six months prior. Participants are assigned to one of two groups. One group receives re-radiochemotherapy with weekly cisplatin or carboplatin if kidney function is impaired followed by pembrolizumab immunotherapy administered intravenously every three weeks for up to two years. The other group receives pembrolizumab alone for up to two years, with the option of up to six additional cycles of cisplatin or carboplatin combined with 5-fluorouracil chemotherapy based on the treating physicians decision. During the study, participants will undergo regular visits and assessments including treatment administration, laboratory tests to monitor organ function and blood counts, and safety evaluations. The main outcome measured is overall survival over two years. Participants will be monitored throughout the treatment period and follow-up to assess treatment effects and safety. The trial is sponsored by Universitt des Saarlandes and will run until 2032.
CONDITIONS
Brief Title
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
Research Team
S
Studienzentrum der Klinik für Strahlentherapie und Radioonkologie
M
Markus Hecht, Prof. Dr. med.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here